Abbreviations and ReferencesAbbreviationsBCNU = carmustine. ReferencesAtkins MB, Lee S, Flaherty, et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial [abstract]. Proc Am Soc Clin Oncol. 2003;22:708. Abstract 2847. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia, Pa: JB Lippincott; 1993:1612-1661. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II
trial of temozolomide in metastatic melanoma. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized
trial of the Dartmouth regimen versus dacarbazine in patients with metastatic
melanoma. Danson S, Lorigan P, Arance A, et al. Randomized phase II study of
temozolomide given every 8 hours or daily with either interferon alfa-2b or
thalidomide in metastatic malignant melanoma. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus
chemotherapy for metastatic melanoma: results from a phase III randomized trial.
Hwu W-J, Krown SE, Menell JH, et al. Phase II study of temozolomide plus
thalidomide for the treatment of metastatic melanoma. Hwu W-J, Krown SE, Panageas KS, et al. Temozolomide plus thalidomide in
patients with advanced melanoma: results of a dose-finding trial. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin and IFN-α2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized phase III trial 18951 [abstract]. Proc Am Soc Clin Oncol. 2003;22:708. Abstract 2848. Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine- platinum versus dacarbazine in malignant melanoma. J Clin Oncol. 1984;2:164-168. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of
temozolomide versus dacarbazine in the treatment of patients with advanced
metastatic malignant melanoma [erratum in Middleton MR, Lunn JM, Morris C, et al. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer. 1998;78:1199-1202. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045; M&B 39831: NSC 362856). Br J Cancer. 1992;65:287-291. Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or
without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma
outpatients: results from an Italian multicenter phase III randomized clinical
trial. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the
United States: issues as we approach the 21st century. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized
trial of the treatment of patients with metastatic melanoma using chemotherapy
with cisplatin, dacarbazine, and tamoxifen alone or in combination with
interleukin-2 and interferon alfa-2b. Rusthoven JJ, Quirt IC, Iscoe NA, et al, for the National Cancer Institute of
Canada Clinical Trials. Randomized, double-blind, placebo-controlled trial
comparing the response rates of carmustine, dacarbazine, and cisplatin with and
without tamoxifen in patients with metastatic melanoma. Sharma RA, Marriott JB, Clarke I, et al. Tolerability of the novel oral thalidomide analog CC-5013 demonstrating extensive immune activation and clinical response [abstract]. Proc Am Soc Clin Oncol. 2003;22:712. Abstract 2862.
|